New combo therapy targets tough leukemia in adults

This study is for adults aged 14 to 60 with a specific, high-risk type of acute lymphoblastic leukemia called Ph-like ALL. Researchers are testing whether adding targeted drugs (olverembatinib or gecacitinib) and venetoclax to standard chemotherapy can help more patients achieve a deep remission without detectable cancer cells. The goal is to improve long-term outcomes, but patients will need ongoing treatment and monitoring.